Deloitte's Biopharma AI Value Estimates Come With a Timing Catch
· Source: marketscale.com
In short
Deloitte's 2024 report estimated that a top-10 biopharma company could capture $5-7 billion in peak AI value over five years, with about 90% concentrated in R&D, manufacturing/supply chain, and commercial functions. Cost reductions were said to appear within one to two quarters, while revenue gains take three to four quarters. McKinsey reported in November 2025 that despite rising AI investment, pharma companies have not yet seen shorter development timelines or better clinical success rates, and AI systems in regulated areas may require validation under frameworks like GAMP.
Read Original Article — Read the full article on the publisher’s site.
In the issue of week 37, 2026: JD.com’s Physical AI and Integrated Platforms Fuel Supply Chain Revolution
Tags: biopharma, supply chain, validation, manufacturing, ROI, life sciences